FINWIRES · TerminalLIVE
FINWIRES

ギブソン・エナジー、第1四半期決算で赤字に転落。配当を発表。

By

-- ギブソン・エナジー(GEI.TO)は月曜日の取引終了後、第1四半期決算が赤字に転落したと発表した。「主な要因は、基礎となる現物資産を裏付ける金融ヘッジによる未実現損失、当四半期に発生したリストラ費用、減価償却費、償却費、減損損失の増加であり、法人税費用の減少によって一部相殺された」としている。 石油インフラ・マーケティング会社である同社の純損失は140万ドルで、前年同期の純利益5000万ドルから赤字に転落した。1株当たりの業績は公表されていない。 3月31日締めの四半期の調整後EBITDAは1億3910万ドルで、前年同期の1億4220万ドルから減少した。同社は、この減少は「一般管理費の増加によるものであり、インフラおよびマーケティング部門の調整後EBITDAの増加によって一部相殺された」としている。 同社はまた、1株当たり0.45ドルの四半期配当を発表し、6月29日営業終了時点の株主名簿に記載されている株主に対し、7月17日に支払う予定である。 「ショーヴァン買収の完了、ハーディスティ・コネクション・プロジェクトの承認、そして社内組織再編は、12月の投資家向け説明会で概説した成長戦略を推進する上で、今四半期に達成した重要なマイルストーンです」と、カーティス・フィリポン最高経営責任者(CEO)は述べ、さらに「最近の地政学的出来事は、北米における安定したエネルギー供給の拡大の重要性を改めて示しています。ギブソンの事業は、顧客がこの世界的なエネルギー需要を満たす上で、有利な立場にあります」と付け加えた。 同社の株価はトロント証券取引所で0.28ドル高の30.18ドルで取引を終えた。

Related Articles

Asia

Lottery Secures Agreement for 40-Year License Extension

Lottery (ASX:TLC) secured an agreement with the Victorian State Government for a 40-year extension of the public lottery license, according to a Tuesday filing with the Australian bourse.The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state, the filing said.Historically, the license has been offered on 10-year terms and was set to expire on June 30, 2028, per the filing.

$ASX:TLC
Asia

Gentrack Group Cuts Fiscal 2026 Revenue Guidance; Plans Buyback; Kiwi Shares Fall 22%

Gentrack Group (NZE:GTK, ASX:GTK) said it now expects fiscal year 2026 revenue of between NZ$229 million and NZ$238 million, lower than its previous guidance, according to a Tuesday filing with the Australian and New Zealand bourses.The company expects fiscal year 2026 recurring revenue to grow by over 10% to around NZ$174 million. It also expects fiscal first-half revenue of around NZ$110 million, of which roughly NZ$85 million would be recurring, per the filing.Gentrack said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of NZ$13.5 million to NZ$20 million, and fiscal first half EBITDA of about NZ$7.8 million, both excluding acquisition costs.The guidance comes as the company has decided "to prioritize growth and global leadership over short-term EBITDA" and continues to invest in international expansion and product development, it said.The company maintained its medium-term target of a more than 15% compound annual growth rate for revenue.Additionally, after the release of fiscal first-half results, Gentrack's board plans to launch an on-market share buyback for up to 5% of the company's issued shares, per the filing.The company's Kiwi shares fell 22% in recent Tuesday trade on the New Zealand bourse.

$ASX:GTK$NZE:GTK
Research

Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.

$VRTX